SCHEMBL3013801

SCHEMBL3013801

O=S(=O)(c1ccc(Cl)c(Cl)c1)C1CCN(c2nc(Cc3ccc(Cl)c(Cl)c3)cs2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.39
AR P10275 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 2/20 0.35
THRB P10828 1/20 0.34
NFE2L2 Q16236 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.33
TRPV1 Q8NER1 1/20 0.33
DNM1L O00429 1/20 0.33
GAA P10253 1/20 0.33
HTR2A P28223 1/20 0.33
HTR7 P34969 1/20 0.33
CHRNA4 P43681 1/20 0.33
SLC6A3 Q01959 1/20 0.33
GHSR Q92847 1/20 0.33
ALDH1A1 P00352 2/20 0.33
ERBB2 P04626 1/20 0.33
EPHA2 P29317 1/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011357 0.94 L3MBTL1 (0.36) L3MBTL1ARLMNAMAPTSMN1; SMN2
SCHEMBL3016860 0.94 L3MBTL1 (0.36) L3MBTL1ARLMNAMAPTSMN1; SMN2
SCHEMBL3017923 0.94 MAPT (0.40) L3MBTL1ARLMNAMAPTSMN1; SMN2
SCHEMBL3017117 0.94 MAPT (0.38) L3MBTL1ARLMNAMAPTNFE2L2
SCHEMBL3014833 0.93 L3MBTL1 (0.35) L3MBTL1ARLMNAMAPTSMN1; SMN2
SCHEMBL3019243 0.93 L3MBTL1 (0.38) L3MBTL1ARLMNAMAPTNFE2L2
SCHEMBL3009908 0.93 LMNA (0.38) L3MBTL1ARLMNAMAPTSMN1; SMN2
SCHEMBL3011442 0.93 SCN1A (0.36) L3MBTL1ARLMNAMAPTTHRB
SCHEMBL3007633 0.93 CACNA1G (0.36) L3MBTL1ARLMNAMAPTSMN1; SMN2
SCHEMBL3016660 0.92 GBA1 (0.38) L3MBTL1ARLMNAMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA L3MBTL1 1847/4885AR 3801/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.